• Victory Square portfolio company Insu Therapeutics received a USPTO Notice of Allowance for its buccal peptide-delivery patent application.
• Allowance supports InsuTab buccal insulin and BuccaGLP buccal semaglutide programs aimed at replacing injections with mouth-lining absorption.
• Insu holds an exclusive worldwide UBC license; Hydreight has disclosed exclusive U.S. distribution rights, subject to development and approvals.
• Hydreight made a strategic investment of C$ 300,000 in Insu, disclosed in March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Victory Square Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: VA66593) on October 08, 2026, and is solely responsible for the information contained therein.